Navigation Links
Better Care Required for Breast Cancer Survivors

A recent study by Germany researchers shows young breast cancer survivors may suffer from more long-term effects than older patients. // As patients may not be getting the appropriate therapy needed for coping with the aftermath of the disease.

Researchers sampled nearly 200 breast cancer patients who had been diagnosed 10 years ago and asked about their physical symptoms and current therapy treatments. Results showed that 65 percent of the respondents were still under a physician's care. Over half of them had physical complaints that included arm problems and fatigue.

It was seen that the age of respondents also made a significant difference. Seventy-one percent of women younger than age 50 reported far greater problems than the older patients. Researchers say lower energy levels of younger patients may be due to the fact that many of them are working and running households, whereas older patients are focusing on taking care of themselves and not necessarily working.

Thus researchers conclude saying "Nowadays all kinds of care programs exist to deal with the physical and emotional problems associated with a new diagnosis of breast cancer. It is important that we make the same kind of facilities available to breast cancer survivors, who despite being free of disease, can still suffer greatly with both physical and psychosocial problems."
'"/>




Page: 1

Related medicine news :

1. Better prostate cancer detection
2. Better Treatment for obesity
3. For a Better Memory
4. Baby Talk Better Than Adult Speech
5. Drug Combo Works Better for children with ADHD, Tics
6. Better skin with lasers
7. Better diabetes treatment promises Vanadium
8. Better Prostate Cancer Test
9. Better Drug for Heart Transplant
10. Better Diet Even Late in Life May Prolong It
11. Two drugs Mays Be Better Than One For Prostate Enlargement
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Better Care Required for Breast Cancer Survivors

(Date:7/31/2015)... , ... July 31, 2015 , ... Ticket Down is ... in Birmingham. The U.S. Women's National Soccer Team will face the Australia Women's National ... Thursday, September 17th at Ford Field in Detroit and the second match will occur ...
(Date:7/31/2015)... ... ... Awarded to only the Top 10 hair transplant practices in the United ... recipients of the Center of Clinical Excellence for ARTAS Robotic Hair Transplantation . ... science of hair transplant. , Parsa Mohebi Hair Restoration is known worldwide for their ...
(Date:7/31/2015)... ... 31, 2015 , ... everMaya ( http://evermaya.com/ ), a Fashion ... will be named for Madeline Stuart, an 18-year-old model from Brisbane, Australia. Ms. ... with Down syndrome, gracing the front pages of publications across the world. everMaya ...
(Date:7/31/2015)... ... July 31, 2015 , ... Indosoft, Inc., is pleased ... in Q-Suite 5.9. Q-Suite is their flagship contact center ACD system for Asterisk-based ... script display logic shows the script components to the agent only when wanted, and ...
(Date:7/31/2015)... Detroit, MI (PRWEB) , ... July 31, 2015 , ... Ticket Down is a reputable ... The U.S. Women's National Soccer Team will face the Australia Women's National Team in conjunction ... by a score of 5-2. Carli Lloyd from the USA team was awarded the ...
Breaking Medicine News(10 mins):Health News:Cheap USA vs. Australia Tickets at Legion Field in Birmingham, AL: Ticket Down Slashes Ticket Prices for Australia vs. USWNT at Legion Field 2Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2
... to Treat Osteosarcoma in More Than 20 YearsIRVINE, Calif., ... IDMI ) today announced that the European ... MEPACT(R) (mifamurtide, L-MTP-PE) for the treatment of patients with ... tumor that typically affects children and young adults. ...
... Clinic Proceedings author reviews the consequencesROCHESTER, Minn., March ... hospital before the treating physician recommends discharge, the ... conditions and the need for readmission, according to ... Mayo Clinic Proceedings. Additionally, the article examines the ...
... 9 Nancy Brinker, famed breast cancer activist and ... be the 2009 recipient of the University of Pittsburgh ... recognition of her outstanding achievements promoting health and preventing ... nearly 30 years ago when she promised her dying ...
... Two Japanese scientists will arrive at the University of ... device that promises to deliver more comprehensive and accurate ... cost of current technologies. , In April, Mikio Kubota ... will join the research team at UH,s Biomedical Imaging ...
... Michigan Catholic Conference Vice President for Public Policy ... regarding an executive order to be issued by ... embryonic stem cell research:"President Obama,s executive order regrettably ... scientific therapeutic advancements. There are endless studies ...
... with MEDITECH Magic through Interface from Iatric Systems, ... Corporation , a leading provider of handheld, ... announced that Ottawa Regional Hospital & Healthcare ... its Barcode Point-of-Care (BPOC) provider to improve bedside ...
Cached Medicine News:Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 2Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 3Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 4Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 5Health News:Patients Being Discharged Against Medical Advice 2Health News:Patients Being Discharged Against Medical Advice 3Health News:Nancy Brinker to receive 2009 Porter Prize 2Health News:UH research team developing new noninvasive brain-mapping technology 2Health News:UH research team developing new noninvasive brain-mapping technology 3Health News:UH research team developing new noninvasive brain-mapping technology 4Health News:Ottawa Regional Hospital & Healthcare Center Moves to a Single Solution for Bedside Patient Safety with IntelliDOT 2Health News:Ottawa Regional Hospital & Healthcare Center Moves to a Single Solution for Bedside Patient Safety with IntelliDOT 3Health News:Ottawa Regional Hospital & Healthcare Center Moves to a Single Solution for Bedside Patient Safety with IntelliDOT 4
(Date:7/31/2015)... 2015  Semler Scientific, Inc. (Nasdaq: SMLR ), ... healthcare insurers and physician groups, today reported financial results ... "In the second quarter of 2015, Semler ... of 54%, quarter over quarter revenue growth of 8%, ... of FloChec® units of 18%," said Doug Murphy-Chutorian, M.D., ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015  Eisai ... Ltd. (Headquarters: Tokyo , President and ... Inc. (Headquarters: San Diego, California , ... HALO") have signed a clinical collaboration agreement to evaluate ... in combination with Halozyme,s investigational drug PEGPH20 (PEGylated recombinant ...
(Date:7/31/2015)... , July 31, 2015  Xencor, Inc. (NASDAQ: ... antibodies for the treatment of autoimmune diseases, asthma and ... Yujiro S. Hata to its board of ... business and corporate development is a tremendous asset to ... and chief executive officer of Xencor. "Xencor faces a ...
Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... - the novel,selective relaxant binding agent (SRBA) being ... Akzo Nobel - demonstrated in,a Phase III pivotal ... as compared to neostigmine, without evidence,of post operative ... The results of this pivotal Aurora trial,were presented ...
... 11, 2007 (MARKET WIRE via COMTEX News,Network) ... target=,"_blank" href="http://www.myriad.com/">www.myriad.com ),announced today that it presented ... a "Randomized Withdrawal" clinical trial,design with a ... the Alzheimer's Association Prevention Conference held,June 9 ...
Cached Medicine Technology:Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial Compared to Neostigmine 2Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial Compared to Neostigmine 3Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 2Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 3Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 4Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 5
PremierEdge™ Stab Knives - 45°....
PremierEdge Stab Knives - 15....
More Info Lacrimal Intubation Set. Size: Probes 23g x 7"....
... use of the Leica CM1900 as well ... the instrument of choice in many routine ... open top stainless steel cryochamber with separate ... ample space for convenient working and storage ...
Medicine Products: